Search

Additional file 5:. Detailed presentation of methylation status of the MAPK11 gene in BRCA, CESC, UCEC and UCS as retrieved from MEEXPRESS analysis. The CpG island probes are presented in red and asterisks annotations represent statistical significance.

Additional file 6:. Heatmap of all 14 methylated MAPK11 probes in BRCA, CESC, UCEC and UCS. The CpG island probes are presented in red.

Additional file 3:. MAPK11 Methylation and correlation of expression with methylation in UCEC. In the top, the CpG1 island with 4 probes is showing a clear positive correlation of the expression of MAPK11 with the methylation status, while at the bottom, the CpG2 island with 6 probes, is showing a clear negative correlation of the expression with the methylation. Overall, a high methylation status has been observed in the first 4 positions targeted by the probes and lower methylation was observed in the following island, indicating that the gene is split into 2 genomic regions of different methylation status.

Additional file 1:. MAPK11 Methylation and correlation of expression with methylation in BRCA. In the top, the CpG1 island with 4 probes is showing a clear positive correlation of the expression of MAPK11 with the methylation status, while at the bottom, the CpG2 island with 6 probes, is showing a clear negative correlation of the expression with the methylation. Overall, a high methylation status has been observed in the first 4 positions targeted by the probes and lower methylation was observed in the following island, indicating that the gene is split into 2 genomic regions of different methylation status.

Additional file 4:. MAPK11 Methylation and correlation of expression with methylation in BRCA, CESC, UCEC and UCS of all the 14 probes.

Additional file 2:. MAPK11 Methylation and correlation of expression with methylation in CESC. In the top, the CpG1 island with 4 probes is showing a clear positive correlation of the expression of MAPK11 with the methylation status, while at the bottom, the CpG2 island with 6 probes, is showing a clear negative correlation of the expression with the methylation. Overall, a high methylation status has been observed in the first 4 positions targeted by the probes and lower methylation was observed in the following island, indicating that the gene is split into 2 genomic regions of different methylation status.

Matrix metalloproteinase (MMP)-mediated degradation of the extracellular matrix is a major factor for tumor development and expansion. This study analysed MMP-10 protein expression and activity in human lung tumors of various grade, stage, and type to address the relationship between MMP-10 and tumor characteristics and to evaluate MMP-10 as a therapeutic target in non small cell lung carcinoma (NSCLC). Unlike the majority of MMPs, MMP-10 was located in the tumor mass as opposed to tumor stroma. MMP-10 protein was observed at low levels in normal human lung tissues and at significantly higher levels in all types of NSCLC. No correlation was observed between MMP-10 protein expression and tumor type, stage, or lymph node invasion. To discriminate between active and inactive forms of MMP-10 in samples of human NSCLC, we have developed an ex vivo fluorescent assay. Measurable MMP-10 activity was detected in 42 of 50 specimens of lung cancer and only 2 of 10 specimens of histologically normal lung tissue. No relationship was observed between MMP-10 activity levels and clinicopathologic characteristics. Our results suggest that MMP-10 is expressed and active at high levels in human NSCLC compared to normal lung tissues, and, as such, is a potential target for the development of novel therapeutics for lung cancer treatment.